Who
Elisabeth Bjork
Director
Company insider
Files Form 4 as: Director, Pharvaris; Director, Rocket Pharmaceuticals.
In numbers
- Trades disclosed
- 31
- Buys
- 2
- Sells
- 2
- Bought
- $103K
- Sold
- $4.6M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 20 Apr 2020
- Last trade
- 17 Sep 2026
- Last filed
- 21 Sep 2026
Companies traded
Activity over time
1 Aug 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Sep 2026filed 21 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code M | $504K35,000 at $14.39 | filing |
| 17 Sep 2026filed 21 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code M | $317K17,500 at $18.14 | filing |
| 17 Sep 2026filed 21 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $2.0M52,500 at $37.89 | filing |
| 17 Sep 2026filed 21 Sep 2026 | PHVS Pharvarisoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,000 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | PHVS Pharvarisoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,500 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | PHVS Pharvarisoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,000 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | PHVS Pharvarisoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,500 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code M | $504K35,000 at $14.39 | filing |
| 17 Sep 2026filed 21 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code M | $317K17,500 at $18.14 | filing |
| 17 Sep 2026filed 21 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $2.0M52,500 at $37.89 | filing |
| 20 May 2026filed 22 May 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code M | $81K10,000 at $8.05 | filing |
| 20 May 2026filed 22 May 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $293K10,000 at $29.32 | filing |
| 20 May 2026filed 22 May 2026 | PHVS Pharvarisoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | PHVS Pharvarisoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code M | $81K10,000 at $8.05 | filing |
| 20 May 2026filed 22 May 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $293K10,000 at $29.32 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $34K10,000 at $3.44 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $34K10,000 at $3.44 | filing |
| 27 Aug 2025filed 27 Aug 2025 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $34K10,000 at $3.41 | filing |
| 18 Jun 2025filed 18 Jul 2025 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
News
Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facilityRCKT · proactiveinvestors.com · 7 Oct 2026
0 headlines in the last 90 days name Elisabeth Bjork; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.